The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.
Howard I. Scher
Research Funding - Medivation
Other Remuneration - Medivation
Karim Fizazi
Consultant or Advisory Role - Astellas Pharma; Medivation
Honoraria - Astellas Pharma; Medivation
Fred Saad
Consultant or Advisory Role - Astellas Pharma; Medivation
Kim N. Chi
Consultant or Advisory Role - Astellas Pharma
Mary-Ellen Taplin
Consultant or Advisory Role - Medivation
Cora N. Sternberg
Honoraria - Astellas Pharma
Andrew J. Armstrong
Consultant or Advisory Role - Medivation (U)
Research Funding - Medivation
Mohammad Hirmand
Employment or Leadership Position - Medivation
Stock Ownership - Medivation
David Forer
Employment or Leadership Position - Medivation
Stock Ownership - Medivation
Johann Sebastian De Bono
Consultant or Advisory Role - Astellas Pharma
Honoraria - Medivation